Thursday 16 October, 2025
Objectives: The atypical antipsychotic drug amisulpride is used orally at a wide range of doses (50-800 mg daily) for the…
Read morePoster: Drug/Disease Modelling - CNS
A Time-to-event Modeling Approach Supporting the Safety Profile of New Deutetrabenazine (AUSTEDO) Titration Schemes in Patients with Tardive Dyskinesia and Huntington’s Disease
Thursday 16 October, 2025
Objectives: Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor used for the treatment of chorea associated with Huntington’s disease…
Read moreBayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker
Thursday 16 October, 2025
Objectives: RO1 is a small molecule, selective GABAA α5 receptor positive allosteric modulator under development for the treatment Neuro-psychiatric disorders….
Read moreA Mechanism-Based PK/PD Model for Posdinemab (JNJ-63733657), a Humanized Monoclonal Antibody Targeting pTau, in healthy and Alzheimer’s Disease Subjects
Thursday 16 October, 2025
Introduction/Objectives: Posdinemab (JNJ-63733657) is a humanized IgG1 monoclonal anti-tau antibody in clinical development for the treatment of Alzheimer’s Disease (AD)1,2….
Read moreIdentifying lack of adherence to antipsychotic treatment using plasma concentrations measurements
Thursday 16 October, 2025
Objectives: To evaluate if measuring antipsychotic plasma concentrations using a diagnostic test can be used as a predictor of treatment adherence,…
Read moreHuman dose prediction approach for a therapeutic monoclonal antibody for a CNS indication inferred using preclinical data including target occupancy
Thursday 16 October, 2025
Introduction: Providing a prediction of the efficacious dose needed to treat patients is a key element to support the developability…
Read moreA Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species
Thursday 16 October, 2025
Objectives: Levodopa, also known as L-dopa or L-3,4-dihydroxyphenylalanine, is the current standard of care for the treatment of Parkinson’s disease (PD)…
Read morePopulation analysis of blood-brain barrier heterogeneity and correlation with imaging characteristics in individuals with central nervous system malignancies.
Thursday 16 October, 2025
Objectives: The blood-brain barrier (BBB) is a critical obstacle to delivery of cytotoxic chemotherapeutics to the central nervous system (CNS)….
Read moreA longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS)
Thursday 16 October, 2025
Objectives: Treatment of patients with MS and development of new therapies have been challenging due to the complexity of the disease,…
Read moreAdequacy of open-loop Target Controlled Infusion devices during anesthesia
Thursday 16 October, 2025
Objectives: Open-loop Target Controlled Infusion (TCI) devices are largely used in clinical practice to aid optimization of propofol dosage for induction…
Read more